References
- Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)-NCI. Available online: https://www.cancer. gov/types/leukemia/hp/child-all-treatment-pdq (accessed on 16.10.2024).
- SEER*Explorer Application. Available online: https://seer.cancer.gov/statistics-network/explorer/application.html?site=92&data_type=1&graph_ type=1&compareBy=sex&chk_sex_1=1&rate_ type=2&race=1&age_range=16&advopt_ precision=1&advopt_show_ci=on&hdn_ view=0&advopt_show_apc=on&advopt_ display=2#resultsRegion0 (accessed on 16.10.2024)
- Forero RM, Hernández M, Hernández-Rivas JM. Genetics of Acute Lymphoblastic Leukemia. In Leukemia. Prof. Margarita Guenova (Ed.); IntechOpen: London, UK, 2013; doi:10.5772/55504
- Studd JB, Cornish AJ, Hoang PH, Law P, Kinnersley B, Houlston R. Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes. Blood Cancer J. 2021;11(11):1-10. doi:10.1038/s41408-021-00570-9
- Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology. 2012;2012(1):389-396. doi:10.1182/asheducation.V2012.1.389.3798360
- Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977-3987. doi:10.1182/blood-2015-02-580043
- Woo JS, Alberti MO, Tirado CA. Childhood B-acute lymphoblastic leukemia: a genetic update. Exp. hema-tol. oncol. 2014;3(1):16. doi:10.1186/2162-3619-3-16
- Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. The Lancet. 2013;381(9881):1943-1955. doi:10.1016/S0140-6736(12)62187-4
- Rob Pieters, Charles G. Mullighan, Stephen P. Hunger. Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL. J. Clin. Oncol. 2023;41:5579-5591. doi:10.1200/JCO.23.01286
- Chang TC, Chen W, Qu C, et al. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J. Clin. Oncol. 2024;42(29):3491-3503. doi:10.1200/JCO.23.02238
- Brady SW, Roberts KG, Gu Z, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54(9):1376-1389. doi:10.1038/s41588-022-01159-z
- Morscio J, Van Vlierberghe P. Chemotherapy at the wheel of ALL relapse. Blood. 2020;135(1):4-5. doi:10.1182/blood.2019003870
- Mullighan CG, Phillips LA, Su X, et al. Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia. Science. 2008;322(5906):1377-1380. doi:10.1126/science.1164266
- Zhang H, Wang H, Qian X, et al. Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing. BMC Cancer. 2020;20(1):211. doi:10.1186/s12885-020-6709-7
- Ueno H, Yoshida K, Shiozawa Y, et al. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2020;4(20):5165. doi:10.1182/bloodad-vances.2019001307
- van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. doi:10.1038/sj.leu.2403202
- Krstevska Bozhinovikj E, Matevska-Geshkovska N, Stojovska M, et al. Presence of Minimal Residual Disease Determined by Next-Generation Sequencing Is Not a Reliable Prognostic Biomarker in Children with Acute Lymphoblastic Leukemia. Leuk Lymphoma 2024 (submitted) doi:10.22541/au.172536128.83797266/v1
- van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901-1928. doi:10.1038/sj.leu.240159
- ALL IC-BFM 2009 A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia; Available online: https://ascopubs.org/doi/suppl/10.1200/JCO.22.01760/suppl_file/protocol1_jco.22.01760.pdf (accessed 16.10.2024)
- Stanulla M, Dagdan E, Zaliova M, et al. IKZF1p-lus Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J. Clin. Oncol. 2018;36(12):1240-1249. doi:10.1200/JCO.2017.74.3617
- Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165-1174. doi:10.1182/blood-2012-05-378943
- Li B, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135(1):41-55. doi:10.1182/blood.2019002220
- Oshima K, Khiabanian H, da Silva-Almeida AC, et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2016;113(40):11306-11311. doi:10.1073/pnas.1608420113
- Sayyab S, Lundmark A, Larsson M, et al. Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia. Sci Rep. 2021;11(1):15988. doi:10.1038/s41598-021-95109-0
- Malinowska-Ozdowy K, Frech C, Schönegger A, et al. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. Leukemia. 2015;29(8):1656-1667. doi:10.1038/leu.2015.107
- Zhu Y, Wang Z, Li Y, et al. The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies. Cancers. 2023;15(4):1219. doi:10.3390/cancers15041219
- Ramírez-Komo JA, Delaney MA, Straign D, et al. Spontaneous loss of B lineage transcription factors leads to pre-B leukemia in Ebf1+/–Bcl-xLTg mice. Oncogenesis. 2017;6(7):e355-e355. doi:10.1038/oncsis.2017.55
- Yang JJ, Bhojwani D, Yang W, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008;112(10):4178-4183. doi:10.1182/blood-2008-06-165027
- Li X, Lin S, Liao N, et al. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children’s leukemia group. Hematol. Oncol. 2024;42(3):e3265. doi:10.1002/hon.3265
- Park KJ, Kim IS. Clinically actionable mutations identified in Korean patients with high-risk acute lymphoblastic leukemia. Ann Oncol. 2018;29:viii370-viii371. doi:10.1093/annonc/mdy286.036
- Vervoort BMT, Butler M, Grünewald KJT, et al. IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia. Haematologica. Published online June 6, 2024. doi:10.3324/haematol.2023.284357
- Stanulla M, Cavé H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood. 2020;135(4):252-260. doi:10.1182/blood.2019000813
- Feng J, Guo Y, Yang W, et al. Childhood Acute B-Lineage Lymphoblastic Leukemia With CDKN2A/B Deletion Is a Distinct Entity With Adverse Genetic Features and Poor Clinical Outcomes. Front Oncol. 2022;12. doi:10.3389/fonc.2022.878098
- Ampatzidou M, Papadhimitriou SI, Paisiou A, et al. The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols. Diagnostics. 2023;13(9):1589. doi:10.3390/diagnostics13091589
- Oshima K, Zhao J, Pérez-Durán P, et al. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nat Cancer. 2020;1(11):1113-1127. doi:10.1038/s43018-020-00124-1